NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
The UG 100 offers a cost-effective and extremely low-error sequencing profile that is a strong fit for NeoGenomics' emerging clinical assay portfolio that requires large amounts of high-fidelity sequencing data. And with the recent launch of the Solaris portfolio of product advancements, Ultima has now increased sensitivity of variant detection with 5x yield improvements for the SNVQ60 ppmSeq™ mode enabling 30X coverage from as little as 2 nanograms of DNA, making the UG 100 a strong fit for applications like liquid biopsy that require finding a 'needle-in-the haystack.'
NeoGenomics' R&D team will use Ultima's UG 100 to enable development of tests spanning the cancer care continuum.
'This collaboration with Ultima, a pioneer in cost-efficient whole genome sequencing, will equip our research and development team with resources to rapidly and efficiently translate innovation for the benefit of patient care,' said Tony Zook, CEO of NeoGenomics. 'With precision oncology testing increasingly being based on next generation sequencing, we are continually looking for targeted opportunities to drive innovation that improve patient outcomes.'
'We are excited to be working with NeoGenomics, a leader in cancer diagnostics with a strong and established footprint in the oncology ecosystem. With the UG 100, NeoGenomics is well-positioned to explore fast-growing markets in oncology diagnostics such as MRD and emerging whole genome sequencing applications,' said Gilad Almogy, CEO of Ultima Genomics. 'Ultima's unique sequencing architecture was designed to specifically meet the needs of cost-effective, large-scale applications and to excel in applications like liquid biopsy requiring extreme accuracy. For oncology applications, our ppmSeq technology offers accuracy at extremely low limits of detection and at low cost, and we believe will be transformational for applications requiring earlier detection such as MRD.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com
Contacts
Ultima Media Contact
Vikki Herrera
408-206-7009
[email protected]
NeoGenomics Investor Contact
Kendra Sweeney
[email protected]
NeoGenomics Media Contact
Andrea Sampson
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/neogenomics-and-ultima-genomics-collaborate-to-expand-clinical-test-offerings-in-oncology-using-the-ug-100-sequencing-platform-302440640.html
SOURCE Ultima Genomics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Great week for The Hain Celestial Group, Inc. (NASDAQ:HAIN) institutional investors after losing 72% over the previous year
Key Insights Given the large stake in the stock by institutions, Hain Celestial Group's stock price might be vulnerable to their trading decisions A total of 14 investors have a majority stake in the company with 52% ownership Recent purchases by insiders AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A look at the shareholders of The Hain Celestial Group, Inc. (NASDAQ:HAIN) can tell us which group is most powerful. The group holding the most number of shares in the company, around 80% to be precise, is institutions. In other words, the group stands to gain the most (or lose the most) from their investment into the company. After a year of 72% losses, last week's 13% gain would be welcomed by institutional investors as a possible sign that returns might start trending higher. Let's take a closer look to see what the different types of shareholders can tell us about Hain Celestial Group. See our latest analysis for Hain Celestial Group What Does The Institutional Ownership Tell Us About Hain Celestial Group? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Hain Celestial Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Hain Celestial Group's historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. Hedge funds don't have many shares in Hain Celestial Group. BlackRock, Inc. is currently the company's largest shareholder with 7.4% of shares outstanding. The Vanguard Group, Inc. is the second largest shareholder owning 7.2% of common stock, and PGGM holds about 4.6% of the company stock. Looking at the shareholder registry, we can see that 52% of the ownership is controlled by the top 14 shareholders, meaning that no single shareholder has a majority interest in the ownership. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Hain Celestial Group While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our most recent data indicates that insiders own some shares in The Hain Celestial Group, Inc.. In their own names, insiders own US$2.8m worth of stock in the US$167m company. Some would say this shows alignment of interests between shareholders and the board, though we generally prefer to see bigger insider holdings. But it might be worth checking if those insiders have been selling. General Public Ownership The general public, who are usually individual investors, hold a 19% stake in Hain Celestial Group. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Hain Celestial Group better, we need to consider many other factors. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Hain Celestial Group you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Nature's Sunshine Products (NASDAQ:NATR) shareholders have earned a 18% CAGR over the last three years
Explore Nature's Sunshine Products's Fair Values from the Community and select yours By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with prowess, you can make superior returns. For example, Nature's Sunshine Products, Inc. (NASDAQ:NATR) shareholders have seen the share price rise 63% over three years, well in excess of the market return (49%, not including dividends). On the other hand, the returns haven't been quite so good recently, with shareholders up just 26%. So let's assess the underlying fundamentals over the last 3 years and see if they've moved in lock-step with shareholder returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over the last three years, Nature's Sunshine Products failed to grow earnings per share, which fell 0.3% (annualized). Based on these numbers, we think that the decline in earnings per share may not be a good representation of how the business has changed over the years. Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics. Do you think that shareholders are buying for the 2.0% per annum revenue growth trend? We don't. While we don't have an obvious theory to explain the share price rise, a closer look at the data might be enlightening. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). Take a more thorough look at Nature's Sunshine Products' financial health with this free report on its balance sheet. A Different Perspective It's nice to see that Nature's Sunshine Products shareholders have received a total shareholder return of 26% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 10% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Nature's Sunshine Products you should know about. Of course Nature's Sunshine Products may not be the best stock to buy. So you may wish to see this free collection of growth stocks. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
22 minutes ago
- Yahoo
JAKKS Pacific (NASDAQ:JAKK) shareholders have earned a 30% CAGR over the last five years
Explore JAKKS Pacific's Fair Values from the Community and select yours It hasn't been the best quarter for JAKKS Pacific, Inc. (NASDAQ:JAKK) shareholders, since the share price has fallen 19% in that time. But that scarcely detracts from the really solid long term returns generated by the company over five years. In fact, the share price is 268% higher today. Generally speaking the long term returns will give you a better idea of business quality than short periods can. The more important question is whether the stock is too cheap or too expensive today. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the last half decade, JAKKS Pacific became profitable. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. It might be well worthwhile taking a look at our free report on JAKKS Pacific's earnings, revenue and cash flow. What About Dividends? When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for JAKKS Pacific the TSR over the last 5 years was 276%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! A Different Perspective While the broader market gained around 19% in the last year, JAKKS Pacific shareholders lost 22% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 30%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand JAKKS Pacific better, we need to consider many other factors. Take risks, for example - JAKKS Pacific has 1 warning sign we think you should be aware of. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
